

## **BONESUPPORT HOLDING AB (publ) NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2018 APPOINTED**

**Lund, Sweden, 18.30 CET, 22 November 2017** – BONESUPPORT HOLDING AB (publ), an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that the Nomination Committee for the Annual General Meeting 2018 has been appointed.

According to the Swedish Corporate Governance Code, BONESUPPORT HOLDING AB (publ) shall have a Nomination Committee, the duties of which shall include the preparation and drafting of proposals regarding the election of members of the Board of Directors, the Chairman of the Board of Directors, the Chairman of the General Meeting and Auditors. The Nomination Committee shall also propose fees for Board members and the Auditor and principles for the appointment of the Nomination Committee. At the Annual General Meeting 2017, it was resolved to adopt an instruction for the Nomination Committee according to which the Nomination Committee shall consist of four members representing the three largest shareholders per 30 September 2017, together with the Chairman of the Board of Directors.

Based on the above, the Nomination Committee has been established to consist of:

- Håkan Björklund, Chairman of the Board of Directors
- Jacob Gunterberg, representing HealthCap V LP
- Johan Kördel, representing Lundbeckfonden Invest A/S
- Jonas Jendi, representing Stiftelsen Industrifonden

Jacob Gunterberg has been appointed Chairman of the Nomination Committee.

The Annual General Meeting will be held in Lund on Tuesday 22 May 2018.

Shareholders wishing to submit comments to the Nomination Committee may do so

-via email to [legal@bonesupport.com](mailto:legal@bonesupport.com) or

-by letter to BONESUPPORT HOLDING AB,  
Att: Nomination Committee,  
Scheelevägen 19,  
Ideon Science Park,  
SE-223 70 Lund, Sweden.

To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than 15 February 2018. The Nomination Committee's proposals will be presented in the notice convening the Annual General Meeting and on the company's website.

### **For more information contact:**

Richard Davies, CEO

+46 (0) 46 286 53 71

Björn Westberg, CFO

+46 (0) 46 286 53 60

[ir@bonesupport.com](mailto:ir@bonesupport.com)

### **Citigate Dewe Rogerson**

Pip Batty, David Dible, Marine Perrier

+44 (0)20 7282 1022

[bonesupport@citigatedewerogerson.com](mailto:bonesupport@citigatedewerogerson.com)

The information in the press release is such that BONESUPPORT HOLDING AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CET on July 31, 2017.

The information was submitted for publication, through the agency of the contact persons set out above, at 18.30 CET on November 22, 2017.

### **About BONESUPPORT™**

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT's marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G\* and CERAMENT® V\* are all based on the Company's novel and proprietary CERAMENT technology platform.

The Company's products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT's total sales increased from SEK 41 million in 2014 to SEK 105 million in 2016, representing a compound annual growth rate of 60 percent. The Company's financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

The Company's research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker "BONEX" (ISIN code: SE0009858152). Further information is available at [www.bonesupport.com](http://www.bonesupport.com)

\*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States

BONESUPPORT™ and CERAMENT® are registered trademarks.